ArticleNPJ precision oncology2026
Design and evaluation of a custom circulating tumour DNA assay to detect endometrial cancer recurrence.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liquid Biopsy for Minimal Residual Disease Assessment in Endometrial and Cervical Cancers: Molecular Rationale, Clinical Evidence, and Translational Barriers.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Circulating tumour DNA (ctDNA) has high sensitivity to detect endometrial cancer (EC) recurrence. An EC-specific ctDNA panel (ECctDNA-panel) was designed using TCGA/CPTAC mutation profile datasets and whole exome sequencing data from primary ECs. The ECctDNA-panel was tested using commercial standards to determine the detection limit for known driver variants, before investigating the plasma cell free DNA (cfDNA) from patients with/without recurrence. The ECctDNA-panel was able to detect EC hotspot mutations at >1% AF in 100% (42/42) of primary tumours tested. The ctDNA standards confirmed detection as low as 0.74% VAF in 5 ng template DNA. The ECctDNA-panel detected hotspot variants in 10/14 patients with recurrence and in 1/25 without recurrence: sensitivity/specificity 71.4%/96% and accuracy 87.2%. Potentially actionable mutations were identified in 8/10 ctDNA positive recurrences. We report the development of an ECctDNA-panel that has a high diagnostic accuracy to detect EC recurrence and could be utilised to guide patient's further management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.